igm biosciences news - Search News

IGM Biosciences to cut 73% of workforce

IGM Biosciences to cut 73% of workforce as latest pivot fails to pan out

IGM Biosciences is again cutting staff as it scraps an autoimmune-drug trial after failing to achieve the desired results.

YAHOO!Finance · 6h

IGM Biosciences Shares Drop 68% as Company Halts Key Programs and Cuts Workforce

The company is reducing its workforce by 73% and evaluating strategic alternatives to preserve shareholder value.

Lupus Foundation of America · 10h

IGM Biosciences Halts Development of Two Investigational Treatments for People with Autoimmune and Inflammatory Diseases

IGM Biosciences announced the discontinuation of imvotamab and IGM-2644 for autoimmune and inflammatory diseases, including lupus.

MarketWatch · 12h

IGM Biosciences Shares Down 69% Following Treatment Development Halt, Workforce Reduction

IGM Biosciences shares dived 69% in premarket trading a day after the company said it would halt development of two of its treatments. Shares were trading around $1.94. The stock is up 1.5% on the year.

Seeking Alpha on MSN · 1d

IGM Biosciences cuts workforce, halts a couple of product developments

IGM Biosciences (NASDAQ:IGMS) announced that it is currently evaluating internal options as well as potential strategic alternatives. Under these changes, it will halt further development of imvotamab,

IGM, BMO Capital downgraded and Jefferies Financial Group

The Armenian Reporter · 5h

Jefferies Financial Group Reiterates “Hold” Rating for IGM Biosciences (NASDAQ:IGMS)

IGM Biosciences (NASDAQ:IGMS – Get Free Report)‘s stock had its “hold” rating reiterated by Jefferies Financial Group in a report released on Friday,Benzinga reports. They currently have a $2.00 target price on the stock,

Business Insider · 7h

IGM Biosciences downgraded to Hold from Buy at Jefferies

Jefferies downgraded IGM Biosciences (IGMS) to Hold from Buy with a price target of $2, down from $48, after the company discontinued all

Fintel on MSN · 11h

BMO Capital Downgrades IGM Biosciences (IGMS)

Fintel reports that on January 10, 2025, BMO Capital downgraded their outlook for IGM Biosciences (NasdaqGS:IGMS) from Outperform to Market Perform. Analyst Price Forecast Suggests 224.55% Upside As of December 23,

IGM Biosciences Stock: Bad News With No Turnaround In Sight

IGM Biosciences has halted all oncology programs and faces a significant pipeline upheaval. Read why I maintain my Sell ...

BioSpace8h

IGM Biosciences Lays Off 73% of Staff, Shrinks Pipeline

Staff cuts could leave IGM Biosciences with fewer than 55 employees. The company is also halting development of two ...

FierceBiotech5h

IGM, Y-mAbs, Passage Bio and more telegraph staff cuts amid restructuring spree

Just two weeks into 2025, January is proving why it’s earned a reputation as the worst month for layoffs. | Just two weeks ...

GlobalData on MSN10h

IMG Biosciences enacts massive lay-offs after Phase I trial failure

Following the negative Phase I trial outcome for its autoimmune disease treatment, the company is cutting 73% of jobs.

4hon MSN

IGM Bio plunges as Wall Street downgrades on portfolio shakeup

IGM Biosciences (IGMS) stock faces sharp selloff as the company abandons two therapeutic candidates, triggering Wall Street ...

IGM Biosciences price target lowered to $2 from $12 at Truist

Truist analyst Asthika Goonewardene lowered the firm’s price target on IGM Biosciences (IGMS) to $2 from $12 and keeps a Hold rating on the ...

Geode Capital Management LLC Buys 28,118 Shares of IGM Biosciences, Inc. (NASDAQ:IGMS)

Geode Capital Management LLC raised its stake in shares of IGM Biosciences, Inc. (NASDAQ:IGMS – Free Report) by 7.6% in the third quarter, Holdings Channel reports. The institutional investor owned ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

IGM Biosciences to cut 73% of workforce

IGM, BMO Capital downgraded and Jefferies Financial Group

Related topics